aid: aspen-neuroscience
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/aspen-neuroscience.png
name: Aspen Neuroscience
description: 'Aspen Neuroscience is a clinical-stage biotechnology company developing personalized
  regenerative cell therapies for Parkinson''s disease. Its lead candidate, ANPD001, is an autologous
  induced pluripotent stem cell (iPSC)-derived neuron replacement therapy that uses a patient''s own
  cells to restore dopamine function without requiring immunosuppression, with manufacturing designed
  for scalable, reproducible production. The company was surfaced as a portfolio company of GV (Google
  Ventures) and added to the API Evangelist network. It operates a corporate website only and publishes
  no public developer API, documentation, or specification surface at this time; artifact coverage here
  is limited to domain/identity signals.'
url: https://raw.githubusercontent.com/api-evangelist/aspen-neuroscience/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Life Sciences
- Biotechnology
- Cell Therapy
- Regenerative Medicine
- Neuroscience
- Parkinson's Disease
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/aspen-neuroscience-domain-security.yml
- type: Website
  url: https://aspenneuroscience.com
- type: Blog
  url: https://aspenneuroscience.com/news-media/press-releases/
- type: Support
  url: https://aspenneuroscience.com/contact-us/
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence